116 related articles for article (PubMed ID: 2507819)
21. [Evaluation of clinical efficacy of rifampicin in the treatment of nontuberculous mycobacteriosis from in vitro susceptibility testing].
Tsukamura M
Kekkaku; 1989 Jul; 64(7):453-8. PubMed ID: 2585946
[TBL] [Abstract][Full Text] [Related]
22. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
[TBL] [Abstract][Full Text] [Related]
23. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex.
Tsukamura M
Am Rev Respir Dis; 1988 Jan; 137(1):144-8. PubMed ID: 3337455
[TBL] [Abstract][Full Text] [Related]
24. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs.
Heifets L
Antimicrob Agents Chemother; 1988 Aug; 32(8):1131-6. PubMed ID: 2461162
[TBL] [Abstract][Full Text] [Related]
25. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].
Truffot-Pernot C; Giroir AM; Maury L; Grosset J
Rev Mal Respir; 1988; 5(4):401-6. PubMed ID: 2845531
[TBL] [Abstract][Full Text] [Related]
26. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method.
van Klingeren B; Dessens-Kroon M; van der Laan T; Kremer K; van Soolingen D
J Clin Microbiol; 2007 Aug; 45(8):2662-8. PubMed ID: 17537932
[TBL] [Abstract][Full Text] [Related]
27. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis.
Heifets LB; Lindholm-Levy PJ; Flory M
Am Rev Respir Dis; 1991 Feb; 143(2):268-70. PubMed ID: 1899326
[TBL] [Abstract][Full Text] [Related]
28. [Drug susceptibility test for Mycobacterium tuberculosis using non-radioactive substance, alpha-antigen].
Shigeto E; Taska H
Kekkaku; 1996 Mar; 71(3):245-52. PubMed ID: 8901226
[TBL] [Abstract][Full Text] [Related]
29. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Sato K; Ogasawara K; Akaki T; Tomioka H
Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility testing of Mycobacterium tuberculosis complex strains isolated from seals to antituberculosis drugs.
Bernardelli A; Morcillo N; Loureiro J; Quse V; Davenport S
Biomedica; 2004 Jun; 24 Supp 1():85-91. PubMed ID: 15495576
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of antimicrobial agents against mycobacteria.
Casal M; Rodríguez F; Gutierrez J; Ruíz P; Villalba R
Drugs Exp Clin Res; 1988; 14(12):741-5. PubMed ID: 3150951
[TBL] [Abstract][Full Text] [Related]
32. [Differentiation between Mycobacterium malmoense and Mycobacterium nonchromogenicum by ethambutol susceptibility].
Yamori S; Tsukamura M
Kekkaku; 1989 Feb; 64(2):95-7. PubMed ID: 2733305
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of cycloserine in the treatment of infections caused by nontuberculous mycobacteria viewed from in vitro experiments].
Tsukamura M
Kekkaku; 1989 May; 64(5):345-9. PubMed ID: 2507817
[TBL] [Abstract][Full Text] [Related]
34. The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient.
Viveiros M; Martins M; Couto I; Kristiansen JE; Molnar J; Amaral L
In Vivo; 2005; 19(4):733-6. PubMed ID: 15999542
[TBL] [Abstract][Full Text] [Related]
35. [Radiometric determination of Mycobacterium avium-intracellulare and Mycobacterium xenopi sensitivity to antitubercular agents].
Kubín M; Lindholm-Levy P; Heifets LB
Epidemiol Mikrobiol Imunol; 1994 Sep; 43(3):104-6. PubMed ID: 7953081
[TBL] [Abstract][Full Text] [Related]
36. [Epidemiology of resistance to antituberculosis drugs in Mycobacterium tuberculosis complex strains isolated from adenopathies in Djibouti. Prospective study carried out in 1999].
Koeck JL; Bernatas JJ; Gerome P; Fabre M; Houmed A; Herve V; Teyssou R
Med Trop (Mars); 2002; 62(1):70-2. PubMed ID: 12038183
[TBL] [Abstract][Full Text] [Related]
37. Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex.
Heifets LB; Iseman MD; Lindholm-Levy PJ
Drugs Exp Clin Res; 1987; 13(9):529-38. PubMed ID: 3428133
[TBL] [Abstract][Full Text] [Related]
38. Paradoxical effect of Tween 80 between the susceptibility to rifampicin and streptomycin and the susceptibility to ethambutol and sulfadimethoxine in the Mycobacterium avium-Mycobacterium intracellulare complex.
Yamori S; Tsukamura M
Microbiol Immunol; 1991; 35(10):921-6. PubMed ID: 1779893
[TBL] [Abstract][Full Text] [Related]
39. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
40. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
Chen P; Gearhart J; Protopopova M; Einck L; Nacy CA
J Antimicrob Chemother; 2006 Aug; 58(2):332-7. PubMed ID: 16751637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
